Patents by Inventor Paul F. Miller

Paul F. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
    Publication number: 20240110192
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: May 10, 2023
    Publication date: April 4, 2024
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA
    Publication number: 20240076645
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: December 19, 2022
    Publication date: March 7, 2024
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • Bacteria engineered to treat metabolic diseases
    Patent number: 11896627
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: February 13, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Elizabeth Rowe, Yves Millet, Adam B. Fisher
  • Bacteria engineered to treat a disease or disorder
    Patent number: 11883439
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: January 30, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Bacteria for the treatment of disorders
    Patent number: 11879123
    Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 23, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe
  • Bacteria engineered to treat diseases associated with hyperammonemia
    Patent number: 11845964
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: December 19, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • BACTERIA ENGINEERED TO SECRETE ACTIVE PROTEINS
    Publication number: 20230332164
    Abstract: Recombinant bacteria capable of producing effector molecules, which are secreted as therapeutically active polypeptides, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, cancer and/or metabolic diseases, are disclosed.
    Type: Application
    Filed: September 30, 2021
    Publication date: October 19, 2023
    Inventors: Dean Falb, Vincent M. Isabella, Paul F. Miller, Adam B. Fisher, Ning Li, Jose M. Lora
  • Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
    Patent number: 11723932
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: August 15, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li
  • MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
    Publication number: 20230226122
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Application
    Filed: August 2, 2022
    Publication date: July 20, 2023
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
  • Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
    Patent number: 11685925
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 27, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 11618894
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: April 4, 2023
    Assignee: SYNLOGIC OPERATING COMPANY, INC.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
    Publication number: 20230043588
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: June 8, 2022
    Publication date: February 9, 2023
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
    Patent number: 11471494
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 18, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
  • Bacteria engineered to treat liver disease
    Patent number: 11439673
    Abstract: The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts. The invention also provides pharmaceutical compositions comprising the genetically engineered bacteria, and methods of modulating and treating disorders associated with excess ammonia and inflammation in the gut and the liver, including, for example, hepatic encephalopathy, NASH/NAFLD, HCV, and Huntington's disease, in a subject, comprising administering the engineered bacterium to the subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: September 13, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Paul F. Miller, Vincent M. Isabella, Dean Falb, Jonathan W. Kotula, Yossi Dagon
  • BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES
    Publication number: 20220226395
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Application
    Filed: January 26, 2022
    Publication date: July 21, 2022
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Elizabeth Rowe, Yves Millet, Adam B. Fisher
  • Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
    Patent number: 11384359
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: July 12, 2022
    Assignee: SYNLOGIC OPERATING COMPANY, INC.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID
    Publication number: 20220168362
    Abstract: The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding a branched chain amino acid catabolism enzyme. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of branched chain amino acids using the pharmaceutical compositions disclosed herein.
    Type: Application
    Filed: December 10, 2021
    Publication date: June 2, 2022
    Inventors: Dean Falb, Paul F. Miller, Yves Millet, Vincent M. Isabella, Jonathan W. Kotula, Alex Tucker
  • Bacteria engineered to treat metabolic diseases
    Patent number: 11291693
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 5, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet, Adam Fisher
  • Bacteria engineered to treat diseases associated with hyperammonemia
    Patent number: 11060073
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: July 13, 2021
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA
    Publication number: 20210180033
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 17, 2021
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani